Phase 3 N=150 Effectiveness of Gabapentin When Used With Naltrexone to Treat Alcohol Dependence Compared to Placebo and Naltrexone Alone
Alcohol Dependence
Primary: Time to Relapse to Drinking — 69.9; 59.6; 57.3 days — p=0.04
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=714 A Safety and Efficacy Study of Canagliflozin in Older Patients (55 to 80 Years of Age) With Type 2 Diabetes Mellitus
Diabetes Mellitus, Type 2
Primary: Change in HbA1c From Baseline to Week 26 — -0.03; -0.60; -0.73 Percent — p=<0.001
Phase 3 N=600 Safety, Tolerability, and Immunogenicity of a Booster Dose of Zoster Vaccine, Live (V211-029)
Herpes Zoster · Varicella-zoster Vaccine
Primary: Geometric Mean Titer (GMT) of the Antibody Responses to Varicella-Zoster Virus (VZV) — 248.0; 254.2; 389.1; 368.6 gpELISA Units/mL — p=<0.001
Phase 3 N=2,017 A Long Term Study of a Medication for Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
Attention Deficit Hyperactivity Disorder
Primary: Percentage of Participants Who Maintain a Satisfactory Response During the Double-Blind Maintenance/Randomized Withdrawal Period — 64.3; 50.0 percentage of responders…
Phase 3 N=469 The CANTATA-MSU Trial (CANagliflozin Treatment And Trial Analysis - Metformin and SUlphonylurea)
Diabetes Mellitus, Type 2
Primary: Change in HbA1c From Baseline to Week 26 — -0.13; -0.85; -1.06 Percent — p=<0.001
Phase 3 N=200 Study of a Single Dose of Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine (SP284) in Japanese Subjects
Meningitis · Meningococcal Meningitis · Meningococcal Infections
Primary: Number of Participants With Serum Bovine Albumin Baby Rabbit (SBA-BR) Titers of >=1:128 Following Vaccination With One Dose of Menactra® Vaccine — 177; 2; 4; 154…
Phase 3 N=269 An Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
Diabetes Mellitus, Type 2 · Renal Insufficiency
Primary: Change in HbA1c From Baseline to Week 26 — -0.03; -0.33; -0.44 Percent — p=0.012
Phase 3 N=71 Efficacy of Alogliptin and With Pioglitazone in Patients With Type 2 Diabetes.
Diabetes Mellitus
Primary: Change From Baseline in Postprandial Incremental Area Under the Curve for Total Triglycerides at Week 16. — -39.728; -346.957; -293.439 mg.h/dL — p=<0.001
Phase 3 N=189 Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO)
Macular Edema Secondary to Central Retinal Vein Occlusion
Primary: Percentage of Participants Who Gained at Least 15 Letters in BCVA at Week 24 as Measured by ETDRS Letter Score — 64; 9 percentage of participants — p=< 0.0001
Phase 3 N=308 Determining Optimal Dose and Duration of Diuretic Treatment in People With Acute Heart Failure (The DOSE-AHF Study)
Heart Failure
Primary: Patient Well Being, as Determined by a Visual Analog Scale — 4236; 4372.7; 4170.8; 4429.6 units on a scale
Phase 3 N=441 Efficacy and Safety of Alogliptin Compared to Glipizide in Elderly Diabetics
Diabetes Mellitus
Primary: Change From Baseline in Glycosylated Hemoglobin at Week 52. — -0.14; -0.09 percentage of Glycosylated Hemoglobin
Phase 3 N=123 Study of Two Doses of Menactra® or One Dose of Monovalent Meningococcal Group C Vaccine With Routine Immunizations
Meningitis · Meningococcal Infection
Primary: Geometric Mean Titers of Serum Bovine Albumin Baby Rabbit Titers Following Vaccination With Either One Dose of Menactra® Vaccine at 12 and 18 Months of Age…
Phase 3 N=202 Efficacy and Safety of AL-4943A Ophthalmic Solution in Patients With Allergic Conjunctivitis Using the Conjunctival Allergen Challenge (CAC) Model
Allergic Conjunctivitis
Primary: Mean Ocular Itching at Onset of Action — 0.4; 1.9; 0.4; 0.6 Units on a scale
Phase 3 N=414 Efficacy and Safety of Aclidinium Bromide 400 µg Compared to Placebo and to Tiotropium Bromide in Patients With Stable Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Chronic Obstructive Pulmonary Disease (COPD)
Primary: Change From Baseline in Normalised Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve Over the 24-h Period After 6 Weeks of Treatment — 0.065; 0.055…
Phase 3 N=157 Long-Term Safety and Tolerability of Degarelix One-Month Dosing Regimen in Korean Patients
Prostate Cancer
Primary: Number of Participants With Markedly Abnormal Values in Safety Laboratory Variables — 1; 1; 10; 2 Participants